This summary was created by AI, based on 55 opinions in the last 12 months.
Eli Lilly & Co. (LLY) is a prominent player in the pharmaceutical industry, widely recognized for its strong sales growth driven primarily by demand for diabetes and obesity treatments. Many experts cite the company’s diversified drug portfolio and a promising pipeline as key strengths that position it well within the healthcare sector. Despite its growth potential, analysts caution about high valuation, with multiples trading around 35x to over 50x PE, which some deem excessive for the pharmaceutical space. Additionally, the looming competition in the obesity drug market is a concern, as prices and margins may come under pressure. While short-term sentiment is mixed, several experts suggest that LLY remains a solid long-term investment with substantial upside from current levels, driven by the company's strong fundamentals and ongoing innovations.
He owns a small holding. Likes their growth profile from their weight-loss drug; they will continue to take market share from Novo Nordisk. The big news this week was that drug shortages were over. They lowered the price too. But shares are expensive at 20x PE on 2028 numbers--expensive for a pharmaceutical. It's had a big run, so he's not adding shares, but trimming.
The question was on buying the stock, LLY, or buying the single stock ETF for Eli Lilly which is LLYH. High income and single stock ETF's are somewhat new to the Canadian marketplace. This type of ETF is a way for Canadians to own a U.S. stock listed on the TSX. With LLYH you get exposure to LLY on a Canadian exchange as well as monthly cash flow from options they write on it. So basically it is an individual stock with an option strategy. Also the ETF is a lower priced Canadian product with tax implications. LLAT is the same thing but with more leverage. You give up some upside on the stock but get a big cash flow.
Exited NVO based on stop losses. Market had high expectations, and efficacy numbers came in weaker than anticipated, sold off. LLY is outperforming NVO at this point. NVO is a bit more leveraged to the weight-loss-management drugs, whereas LLY is more diversified.
LLY has strong technical indicators, with 200-week and 200-day MAs moving higher. Still shows strength within his quant screens. Trading at 35x forward PE, with 28-29% growth rate -- pretty impressive; PEG ratio rather low. Dropped below 200-day MA, but that might be temporary. Both names have beta, but likes them long term.
Eli Lilly & Co. is a American stock, trading under the symbol LLY-N on the New York Stock Exchange (LLY). It is usually referred to as NYSE:LLY or LLY-N
In the last year, 69 stock analysts published opinions about LLY-N. 23 analysts recommended to BUY the stock. 23 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Eli Lilly & Co..
Eli Lilly & Co. was recommended as a Top Pick by on . Read the latest stock experts ratings for Eli Lilly & Co..
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
69 stock analysts on Stockchase covered Eli Lilly & Co. In the last year. It is a trending stock that is worth watching.
On 2025-04-01, Eli Lilly & Co. (LLY-N) stock closed at a price of $805.23.
Hold both LLY and NOVO? No. Choose one or the other. LLY sells more diverse drugs and more North American focused.